United States Patent 8,551,957 (DPP-4 inhibitor combination for metabolic disorders): scope of claims and US patent landscape
US Patent 8,551,957 is a composition-plus-method patent that claims a fixed combination of (i) a specific glucopyranosyl-substituted benzene derivative and (ii) a specific DPP-4 inhibitor (both named in the claims), with broad disease coverage across metabolic disorders and diabetes-related complications. The claim set is dominated by broad combination coverage (single dosage form or separate dosage forms) and broad patient-selection language, then narrowed by dose ranges (mg amounts) and some dosing frequency embodiments (once daily).
What does US Patent 8,551,957 claim: composition + fixed combination scope?
Core protected subject matter (Claim 1):
A pharmaceutical composition comprising:
- the glucopyranosyl-substituted benzene derivative
1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene (as written in the claims),
plus
- the DPP IV inhibitor
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (as written in the claims),
or a pharmaceutically acceptable salt thereof.
Two practical legal “entry points” from Claim 1
- Substance lock-in: the combination requires the specific benzene derivative and the specific DPP-4 inhibitor as recited by name (or pharmaceutically acceptable salts).
- Combination format options: subsequent claims explicitly cover both single dosage form and separate dosage forms, reducing design-around space that relies on packaging or co-administration structure.
How broad are the “single vs separate dosage form” claims?
US Patent 8,551,957 explicitly splits combination administration into two embodiments:
Single dosage form
- Claim 2: both components in a single dosage form.
- Claim 20/21/30/38/40: oral and solid-form embodiments (with single dosage form explicitly stated in Claim 30 and repeated in product embodiments like Claims 38 and 40).
Separate dosage forms
- Claim 3: each component in separate dosage forms.
- Method claims also allow “combination or alternation,” which functionally covers both co-dosing and staggered regimens.
Impact: A product that avoids patent risk by “separating tablets into different packages” still falls within Claim 3 and within the method claims that use “combination or alternation.”
What formulations and dosage strengths are covered?
Oral and solid-form limitations
- Claim 20: oral administration.
- Claim 21: oral administration in solid form.
Dose ranges (composition-level)
- Claim 22: benzene derivative 5 to 50 mg.
- Claim 23: DPP-4 inhibitor 0.5 to 10 mg.
- Claim 24: both dose ranges together (5 to 50 mg + 0.5 to 10 mg).
Discrete strength examples (composition-level)
- Benzene derivative: 5, 10, 15, 20, 25, 50 mg (Claim 31).
- Benzene derivative: 10 mg (Claim 32).
- Benzene derivative: 25 mg (Claim 33).
- DPP-4 inhibitor: 0.5, 1, 2.5, 5, 10 mg (Claim 34).
- DPP-4 inhibitor: 1, 2.5, 5 mg (Claim 35).
- DPP-4 inhibitor: 5 mg (Claim 36).
Combination strength product embodiments
- Claim 37: 10 mg benzene derivative + 5 mg DPP-4 inhibitor (salt allowed).
- Claim 38: same strength, explicitly in a single dosage form.
- Claim 39: 25 mg benzene derivative + 5 mg DPP-4 inhibitor.
- Claim 40: same strength, explicitly in a single dosage form.
Impact: The claim set supports both “range” protection and multiple “hard-coded” strengths, including the 10/5 mg and 25/5 mg combos, with single dosage form explicitly captured for those strengths.
What method-of-use territory is covered: diabetes, prediabetes, metabolic syndrome, and complications?
Broad disease categories (Claim 4)
A method for slowing progression, delaying, or treating a metabolic disorder selected from:
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Impaired glucose tolerance
- Impaired fasting blood glucose
- Hyperglycemia
- Overweight
- Obesity
- Metabolic syndrome
The administration event: administering the benzene derivative of Claim 1 in combination or alternation with the DPP-4 inhibitor of Claim 1.
Expanded glycemic control (Claim 5)
Improving glycemic control and/or reducing:
- fasting plasma glucose
- postprandial plasma glucose
- HbA1c
Disease progression to type 2 diabetes (Claim 6)
Slowing, delaying, or reversing progression from:
- impaired glucose tolerance
- impaired fasting blood glucose
- insulin resistance
- metabolic syndrome
to type 2 diabetes mellitus
Complications of diabetes (Claim 7)
Slowing/delaying/treating complications including:
- cataracts
- micro- and macrovascular diseases:
- nephropathy
- retinopathy
- neuropathy
- tissue ischemia
- arteriosclerosis
- myocardial infarction
- stroke
- peripheral arterial occlusive disease
Weight effects (Claim 8)
Reducing body weight or facilitating weight reduction.
Beta cell and insulin secretion protection (Claim 9)
Slowing/delaying/treating degeneration of pancreatic beta cells and/or restoring function, improving insulin secretion.
Liver fat / abnormal accumulation (Claim 10)
Treating diseases/conditions attributed to abnormal accumulation of liver fat.
Insulin sensitivity and hyperinsulinemia (Claim 11)
Maintaining/improving insulin sensitivity and treating hyperinsulinemia and insulin resistance.
A direct “type 2 diabetes” method claim (Claim 25)
Treating type 2 diabetes via the claimed combination.
Impact: The method claims cover a wide therapeutic surface. A challenge to enforceability typically turns on whether the claimed combination actually produces the stated effects, but scope-wise the patent is written to read across multiple diabetes-related phenotypes and endpoints.
How do the dependent method claims narrow the patient population?
Claims 12–19 and 16–19 (and mirrored language across Claims 13–19) contain repeated patient-selection criteria. These are structured as:
- Diagnosed overweight/obesity/visceral obesity/abdominal obesity; OR
- Exhibiting one or more biomarker thresholds:
- fasting blood glucose/serum glucose >110 mg/dL (in particular >125 mg/dL)
- postprandial plasma glucose ≥140 mg/dL
- HbA1c ≥6.5% (in particular ≥8.0%)
- plus a set of metabolic risk markers:
- triglycerides ≥150 mg/dL
- HDL below cutoffs (female <40; male <50)
- blood pressure ≥130/85 mm Hg
- fasting glucose ≥110 mg/dL
- Specific comorbidity markers may stack (one, two, or three or more).
- Treatment-history qualifiers:
- metformin contraindicated and/or intolerance to therapeutic doses
- insufficient glycemic control despite monotherapy with SGLT2 inhibitor
- insufficient glycemic control despite monotherapy with DPP-4 inhibitor
Impact: Enforcement can target not just disease labels (T2D, prediabetes) but also real-world patient archetypes that fail common monotherapies or are metformin-ineligible.
How does the patent cover dosing frequency and specific daily regimens?
Method dosing frequency is present in dependent claims:
- Claim 26: type 2 diabetes method.
- Claim 26 further dependence (Claim 26/41): once daily for benzene derivative (Claim 41).
- Claim 27 dependence (Claim 44/46): DPP-4 inhibitor once daily.
- Claim 28 dependence (Claim 47/48): both agents once daily with specified mg amounts.
Benzene derivative once-daily dose examples
- Claim 41: 5, 10, 15, 20, 25, 50 mg once daily.
- Claim 42: 10 mg once daily.
- Claim 43: 25 mg once daily.
DPP-4 inhibitor once-daily dose examples
- Claim 44: 0.5, 1, 2.5, 5, 10 mg once daily.
- Claim 45: 1, 2.5, 5 mg once daily.
- Claim 46: 5 mg once daily.
Combination once-daily examples
- Claim 47: 10 mg benzene derivative + 5 mg DPP-4 inhibitor once daily.
- Claim 48: 25 mg benzene derivative + 5 mg DPP-4 inhibitor once daily.
Impact: The claims create a tight enforcement pathway against generic or follow-on formulations if they adopt the same dose pairings and once-daily schedule.
What is the practical claim hierarchy and what does it mean for infringement risk?
Claim 1 (independent) sets the combination boundary
If a product uses the exact benzene derivative + exact DPP-4 inhibitor (or salt) in any dosage form that meets downstream limitations, infringement risk follows.
Claims 2–3 expand formulation/administration structure
Single or separate dosage forms both appear.
Claims 4–11 establish broad endpoint coverage
These claims are not limited to one endpoint (e.g., HbA1c) but include progression, complications, weight, beta-cell protection, liver fat.
Claims 12–19 add patient qualifiers
These provide narrower route for enforcement but also create multiple fact patterns to establish infringement.
Claims 20–24 and 31–40 anchor product-specific commercial parameters
Oral, solid form, mg ranges, and specific strength combinations.
Net: The patent is written to cover both “what the product is” (composition) and “how it is used” (methods), with substantial overlap.
How strong is the claim estate based on breadth and specificity tradeoffs?
Strength factors
- Specific named actives in combination: the scope is specific to the two molecules, which can strengthen the “teach-to-infringe” narrative but also narrows the universe of potential noninfringing combinations.
- Multiple claim types: composition (Claims 1–3, 20–24, 31–40, 37–40) plus extensive method claims (Claims 4–19, 25–28, 41–48).
- Multiple dosing anchors: both ranges and discrete strengths plus once-daily schedules.
Vulnerability factors inherent to the text
- Broad disease coverage is extensive (from T1D to liver fat and vascular complications). If the claimed combination’s evidentiary support in the specification is thin, a validity challenge could target written description/enablement rather than narrowing interpretation.
Patent landscape beyond US 8,551,957: what else typically controls freedom to operate here?
Without the full bibliographic record (other US patents in the same family, continuations, divisionals, related PCT filings, and the prosecution history) and without the Orange Book listing tied to any approved NDA/ANDA, a complete US landscape cannot be produced from the claim text alone. The claim set you provided is sufficient to characterize scope of 8,551,957, but not sufficient to enumerate the surrounding “genera” of patents or their expiration-by-expiration status.
Accordingly, this analysis is limited to the scope and practical legal read-across of US 8,551,957 claims as written.
Key Takeaways
- US 8,551,957 protects a fixed combination of two specifically named small molecules for metabolic disorders, with broad method-of-use coverage spanning T1D/T2D, prediabetes, insulin resistance, obesity, liver fat, and multiple diabetes complications.
- The patent captures both single-dose-form and separate-dose-form regimens, using “combination or alternation” in the method claims.
- Product commercialization risk concentrates around oral solid formulations, mg ranges (benzene derivative 5–50 mg; DPP-4 inhibitor 0.5–10 mg), and specific strength pairs (notably 10 mg + 5 mg and 25 mg + 5 mg), including once-daily dosing embodiments.
- Patient-selection dependent claims target real-world niches: overweight/obesity phenotypes, biomarker thresholds, metformin-ineligible patients, and inadequate responders to SGLT2 inhibitor or DPP-4 inhibitor monotherapy.
FAQs
1) Does infringement require both drugs to be in one pill?
No. Claim 3 covers separate dosage forms, and method claims cover combination or alternation.
2) Are salts of the named actives included?
Yes. Claim 1 and the composition embodiments state “pharmaceutically acceptable salt thereof.”
3) Are method claims limited to type 2 diabetes only?
No. Claim 4 covers a metabolic disorder set including type 1 diabetes mellitus and type 2 diabetes mellitus, plus prediabetes states and metabolic syndrome.
4) What endpoints are specifically claimed?
HbA1c and plasma glucose endpoints are in Claim 5, while progression, complications, weight, beta-cell function, insulin sensitivity, and liver-fat associated conditions are in Claims 6–11.
5) What dosing parameters are explicitly claimed?
Benzene derivative: 5–50 mg composition range; DPP-4 inhibitor: 0.5–10 mg composition range; and multiple discrete strength and once-daily embodiments (including 10 mg + 5 mg and 25 mg + 5 mg).
References
- United States Patent 8,551,957. Claims text provided in the prompt (composition and method claims).
